One Stop Systems (($OSS)) has held its Q4 earnings call. Read on for the main highlights of the call. The recent earnings call for One Stop ...

Universal Insurance faces risks with Florida concentration despite revenue growth. Read more on UVE's Q4 results, ...

Ruben Amorim's arrival at Old Trafford was met with much fanfare, but it feels like little has changed in the four months ...

Savings banks in South Korea suffered a net loss for the second consecutive year in 2024, and their asset quality worsened ...

The dental industry is quickly evolving to respond to the needs of patients and dental professionals, while also dealing with ...

Investment returns totalled £4.9 billion, also down from £5.3 billion in 2023. Lloyd’s attributed the decrease to ...

The major claims ratio increased to 7.8%, reflecting the impact of large-scale catastrophe events, including hurricanes ...

Meanwhile, investment return declined to GBP4.9 billion last year from GBP5.3 billion the year before. Lloyd's said that, while higher interest rates helped investment performance throughout 2024, ...

Supporting another solid underwriting performance, the Lloyd’s investment result was also strong, benefiting from another ...

In reporting its full-year results for 2024 this morning, the Lloyd's insurance and reinsurance market delivered positive ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study ...